Giorgio Zauli

Potential pathogenetic implications of cyclooxygenase-2 overexpression in B chronic lymphoid leukemia cells.

Stefano A Pileri, Claudio Agostinelli, S. Pileri, 2005, American Journal of Pathology.

The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies.

P. Secchiero, A. Gonelli, G. Zauli, 2008, Current pharmaceutical design.

Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.

P. Secchiero, F. Corallini, G. Zauli, 2009, Blood.

Recent advances in the therapeutic perspectives of Nutlin-3.

P. Secchiero, G. Zauli, Paola Secchiero, 2011, Current pharmaceutical design.

COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-Chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?

P. Secchiero, G. Zauli, B. Bramanti, 2020, International journal of molecular sciences.

Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.

P. Secchiero, F. Corallini, G. Zauli, 2009, Blood.

Tumor necrosis factor alpha (TNF-alpha) activates Jak1/Stat3-Stat5B signaling through TNFR-1 in human B cells.

Francesco Garaci, Marco Marchisio, F. Garaci, 2002, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3

A. Albini, P. Secchiero, F. Corallini, 2007, Circulation research.

microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival.

George A Calin, Kevin R Coombes, Muller Fabbri, 2010, Blood.